BioCryst Pharmaceuticals to Acquire Astria Therapeutics for $700 Million
BioCryst Pharmaceuticals has entered into a definitive agreement to acquire Astria Therapeutics in a cash-and-stock transaction valued at approximately $700 million.
Stocks · News reference
BioCryst Pharmaceuticals presented new real-world evidence demonstrating that patients with hereditary angioedema (HAE) experienced reduced hospitalizations and emergency department visits after initiating or switching to ORLADEYO®.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
BioCryst Pharmaceuticals has entered into a definitive agreement to acquire Astria Therapeutics in a cash-and-stock transaction valued at approximately $700 million.
BioCryst Pharmaceuticals has been recognized as the 'Therapeutics Company of the Year' by the BioTech Breakthrough awards program.
Wedbush maintained its Outperform rating on BioCryst Pharmaceuticals while adjusting its price target to $17 from $18.
BioCryst Pharmaceuticals, Inc. announced its financial results for the third quarter ended September 30, 2026, highlighting continued growth of its ORLADEYO therapy.
Filed: 2026-11-04 AccNo: 0001171843-26-007097 Size: 451 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
BioCryst Pharmaceuticals announced it will present new clinical data regarding its HAE therapy ORLADEYO and its investigational candidate Navenibart at the 2026 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.